As of Thursday, October 08, Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 10.42%, which has investors ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a tech-enabled biopharma company combining automated, experimental biology with artificial intelligence to discover novel treatments that extend beyond our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results